GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Cirrhosis Liver/Systemic Inflammatory Index, TIPS and long term mortality

Systemic Inflammatory Index, TIPS and long term mortality

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated May 1, 2025

Quick Answer

**Systemic Inflammatory Index (SII):** The Systemic Inflammatory Index (SII) is a biomarker that reflects systemic inflammation by combining platelet, neutrophil, and lymphocyte counts into a single formula. It is calculated as: **SII = (Platelet count × Neutrophil count) / Lymphocyte count** SII captures the balance between pro-inflammatory and anti-inflammatory components in the body.


**Systemic Inflammatory Index (SII):**

The Systemic Inflammatory Index (SII) is a biomarker that reflects systemic inflammation by combining platelet, neutrophil, and lymphocyte counts into a single formula. It is calculated as:

**SII = (Platelet count × Neutrophil count) / Lymphocyte count**

SII captures the balance between pro-inflammatory and anti-inflammatory components in the body. Elevated SII values indicate heightened systemic inflammatory activation, which is often associated with poor clinical outcomes, particularly in conditions like cirrhosis, cancer, and cardiovascular diseases. In the context of cirrhosis, elevated SII reflects a state of immune dysregulation and inflammation that exacerbates liver deterioration and contributes to mortality.

---

**Transjugular Intrahepatic Portosystemic Shunt (TIPS):**

TIPS is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding, refractory ascites, and hepatorenal syndrome, in patients with advanced liver disease (cirrhosis). The procedure involves creating a shunt between the portal vein and hepatic vein to reduce portal pressure. While TIPS is effective in managing portal hypertension-related complications, it carries risks such as hepatic encephalopathy and high long-term mortality due to the underlying liver dysfunction and systemic effects.

---

**Short-Term and Long-Term Mortality Associated with TIPS:**

1. **Short-Term Mortality (≤12 months):**

  • The study found that the 6-month mortality rate was **4.8%**, and the 12-month mortality rate was **7.6%**.
  • Early mortality is primarily driven by factors such as liver failure, gastrointestinal bleeding, and hepatorenal syndrome.
  • Inflammatory markers like SII and neutrophil-to-lymphocyte ratio (NLR) were strong predictors of early mortality, indicating that systemic inflammation plays a critical role in short-term outcomes.

2. **Long-Term Mortality (>12 months):**

  • The 18-month mortality rate was **10.8%**.
  • Long-term mortality is influenced by the progressive deterioration of liver function and systemic complications. Over time, nutritional depletion (as assessed by the Prognostic Nutritional Index, PNI) becomes a stronger predictor of mortality, highlighting the interplay between inflammation and malnutrition in cirrhotic patients.
  • The study demonstrated that the predictive accuracy of SII remains robust in long-term mortality prediction when combined with age and the Child-Pugh score in Nomogram 2.

---

**How SII Helps Identify Long-Term Mortality After TIPS:**

SII is a powerful prognostic marker because it reflects systemic inflammatory activation, which worsens liver function and contributes to multi-organ failure in cirrhotic patients. The study identified SII as an independent predictor of 18-month mortality post-TIPS, alongside age and the Child-Pugh score. Here's how SII contributes to long-term mortality prediction:

1. **Mechanistic Role:**

  • Elevated SII indicates an imbalance in platelet, neutrophil, and lymphocyte counts, signifying heightened systemic inflammation. This inflammatory state accelerates hepatic deterioration and worsens outcomes in cirrhotic patients.
  • SII captures the combined effects of immune dysregulation and inflammation, which are central to the progression of liver disease and mortality.

2. **Integration in Prognostic Models:**

  • The study developed two nomograms to predict 18-month mortality:
  • **Nomogram 1:** Child-Pugh score + SII
  • **Nomogram 2:** Age + Child-Pugh score + SII
  • Nomogram 2 demonstrated superior predictive performance, with a C-index of **0.82** and high area under the curve (AUC) values for 6-, 12-, and 18-month mortality prediction.

3. **Enhanced Predictive Accuracy:**

  • Adding SII to traditional prognostic scores like Child-Pugh significantly improved the model's ability to stratify patients into high- and low-risk groups. Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) analyses confirmed that SII enhances prognostic accuracy over the Child-Pugh score alone.

4. **Temporal Dynamics:**

  • SII is more effective in predicting early mortality (≤12 months), while nutritional markers like PNI become stronger predictors beyond one year. This indicates shifting pathophysiological dynamics in cirrhotic patients undergoing TIPS.

5. **Clinical Utility:**

  • Decision curve analysis showed that Nomogram 2 (incorporating SII) provides strong net clinical benefit across multiple risk thresholds. This makes SII a valuable tool for individualized mortality risk estimation and early identification of high-risk patients post-TIPS.

---

**Conclusion:**

SII is a robust systemic inflammatory marker that plays a critical role in predicting both short-term and long-term mortality in cirrhotic patients undergoing TIPS. Its integration into predictive models, alongside age and the Child-Pugh score, enhances risk stratification and supports clinical decision-making. By reflecting the interplay between inflammation and liver dysfunction, SII provides valuable insights into the mechanisms driving mortality and helps identify high-risk patients for early intervention.

Related Q&A

POCUS-Guided AKI Management in Cirrhosis: Hepatology | July 2026

Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...

A Novel Pro-Resolving Target (Annexin A1) for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Distal Esophageal Varices in Fontan Circulation: Hepatology | May 2026

Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...

Annexin A1-A Novel Pro-Resolving Target for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Simvastatin Improves Survival After Variceal Bleeding in Cirrhosis: AJG | July 2026

Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...

Pre-Emptive CRRT Improves Outcomes in ALF with Cerebral Oedema: AP&T | June 2026

Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer